The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | PROTACs as an emerging new drug class to treat hematologic malignancies
John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses proteolysis targeting chimeras (PROTACs) as an emerging drug class for treating hematologic malignancies. This drug class includes BTK degraders, which have shown effective degradation of BTK and high response rates in Phase I trials. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
